Compare SKYH & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYH | RZLT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | 112 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.6M | 326.4M |
| IPO Year | N/A | 2011 |
| Metric | SKYH | RZLT |
|---|---|---|
| Price | $10.54 | $3.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $13.13 | $9.67 |
| AVG Volume (30 Days) | 96.8K | ★ 1.5M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $78.89 | N/A |
| Revenue Next Year | $73.15 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.22 | $1.07 |
| 52 Week High | $12.20 | $11.46 |
| Indicator | SKYH | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 56.96 | 45.14 |
| Support Level | $9.76 | $2.87 |
| Resistance Level | $10.83 | $3.73 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 39.96 | 12.06 |
Sky Harbour Group Corp is an aviation infrastructure company focused on building the first nationwide network of Home Base Operator (HBO) campuses designed exclusively for business aircraft. The company develops, leases, and manages general aviation hangars across the United States, targeting airfields in markets with aircraft populations and high hangar demand. Its HBS campuses include private hangars and offer a range of services tailored to aircraft owners operating from these facilities. The majority of the company's revenue is derived from the leasing of home-based aircraft hangars and through services and products ancillary to its leasing activities.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.